Abstract Despite extensive research into stroke pathology, there have not been any major recent advancements in stroke therapeutics.
Introduction
One of the emerging targets for stroke therapeutics is the inflammatory response originating from the spleen after ischemic injury. However, the exact signaling mechanism from the spleen that contributes to the increased neural injury following stroke is unknown. Molecular and cellular targets have been studied following stroke and none of these studies have yielded results which have aided in the development of new stroke therapies. The various factors in determining the specific cell types and cytokines/chemokines to target, as well as the timing at which they should be targeted, have played a major role in the inability to translate preclinical research into effective stroke therapies to date.
The Initial Cascade of Neural Death Following Stroke
Ischemia produces a hypoxic and glucose-deprived environment that leads to cellular dysfunction and cell death through necrosis or apoptosis. In an attempt to keep up with the high energy demands in the brain, neural cells switch to anaerobic cellular respiration. Cell membranes become damaged from the resulting build up of reactive oxygen and nitrogen free radicals, which leads to cellular edema and necrosis. Additionally, as neurons and astrocytes die, there is a release of glutamate that compromises more neurons through glutamate excitotoxicity. The activation of glutamate receptors leads to excessive intracellular calcium release, edema, and caspase activation, which results in apoptosis [1] . All of these mechanisms lead to early cell death in the core of the infarct, the area directly perfused by the occluded artery. These events occur within the first few hours of stroke and targeting the molecules in this early phase has proven impractical for therapeutic intervention.
However, there is a delayed cellular death that occurs several hours to days after stroke. The initial activation of matrix metalloproteinases (MMPs) opens the blood-brain barrier (BBB) transiently by MMP-2. Later, at 48 h postmiddle cerebral artery occlusion (MCAO), upregulation of MMP-9 leads to a prolonged disruption of the BBB [2] . This break down in the BBB allows neural antigens into the peripheral circulation. The leaky BBB contributes to enhanced neural injury by increasing edema, as intracranial pressure builds from the influx of excess fluid. This BBB dysfunction also allows the peripheral immune system to come in contact with these neural antigens and generate an immune response to the brain, which results in further injury.
The Role of the Spleen in Ischemic Injury
The spleen is secondary immune organ that stores both red and white blood cells. Recent studies have indicated this organ is an active participant in the body's immune reaction to ischemic injury. In 1996, the first study reporting the splenic immune response was associated with increased tissue damage following liver ischemia [3] , but has since been reported in the pathophysiology of stroke [4] [5] [6] . This review delves into the cellular and molecular actions of the spleen, in concert with other immune organs, reacting to ischemic injury to the brain.
The spleen is a highly vascularized secondary peripheral lymphoid organ and is organized into the white pulp and the red pulp. The white pulp consists of T cell zones, or periarteriolar lymphoid sheaths, and B cell follicles; while the red pulp contains B cells, natural killer cells (NK cells), and monocytes/macrophages which are in close proximity to the vasculature. This allows monocytes/macrophages to filter the blood for dying red blood cells, hemoglobin, and antibody-covered bacterial pathogens. Plasma cells, or antibody-producing B cells, are the specific type of B cells found in the red pulp. This location in the spleen allows for rapid delivery of antibodies into circulation [7] . NK cells in the red pulp resemble NK cells found in circulation [8] . The white pulp is split into two areas: one for T cells and another for B cells. The T cell zones allow naïve T cells to be in close proximity to the arteriole blood supply. In addition to T cells, dendritic cells are present in the T cell zones to present naïve T cells with antigens the dendritic cells find in the blood. Once activated, T cells leave the spleen and initiate an immune response [7] .
The splenic capsule is made up of smooth muscles that express α 1 adrenergic receptors. Activation of the α 1 receptors leads to contraction of the smooth muscles and a subsequent decrease in spleen size. In addition to being an immune cell reservoir, the spleen is also reservoir for red blood cells. During times of physical stress, the spleen has been shown to contract, releasing red and white blood cells into systemic circulation [9, 10] . The spleen is the largest reservoir of undifferentiated tissue-nonspecific monocytes and contains half of the monocytic cell population. These cells have been shown to be released following myocardial infarction (MI) and have detrimental effects on the damaged tissue, as well as preventing tissue healing [11] .
As stated previously, the spleen generates a proinflammatory response to various ischemic injuries. Splenectomy is protective in other ischemic injuries including the liver, intestines, kidneys, and heart. The initial report of cellular protection following splenectomy showed that removal of the spleen immediately prior to ischemic/reperfusion (IR) injury of the liver reduced the infiltration of polymorphonuclear cells into the liver following IR [3] . A later study found hepatic IR was also associated with injury to other organs including the kidneys, lungs, and intestines. Splenectomy reduced cell apoptosis and caspase 3 signaling in all four organs [12] .
Intestinal IR has been linked to acute lung injury. Kupffer cells in the liver become inflammatory in response to intestinal IR. Blocking Kupffer cell activation using gadolinium chloride or splenectomy prior to intestinal IR resulted in significantly decreased injury to the lungs [13] . Renal IR also induces an inflammatory phenotype in Kupffer cells. Again, the gadolinium chloride or splenectomy decreased histopathological changes caused by renal IR [14] . The intestinal and renal IR studies both concluded that splenectomy was protective due to the removal of a large reservoir of monocytes. Monocytes have also been found to play an important role in exacerbating injury following MI. Sequestering splenic monocytes in the spleen with enalapril, an angiotensin-converting enzyme (ACE) inhibitor, or their removal via splenectomy prior to experimental MI, decreased inflammation and infarct size [15] .
Monocytes have been shown to play a detrimental role in ischemic pathology in many other organs. As the spleen contains a majority of the monocytes in the body, this suggests these cells are responsible for IR organ damage. This has lead to the conclusion that the spleen is an important mediator of post-IR injury tissue damage. Additionally, blocking Kupffer cell activation with gadolinium chloride was as efficacious as splenectomy in renal and intestinal IR. These studies indicate that the spleen activates Kupffer cells to a pro-inflammatory state resulting in increased tissue damage following IR injuries.
Removal of the spleen is also protective in variety of brain injury models: permanent middle cerebral artery occlusion (pMCAO), transient middle cerebral artery occlusion (tMCAO), intracerebral hemorrhage (ICH), and traumatic brain injury (TBI) [4] [5] [6] [16] [17] [18] . Splenectomy prior to pMCAO in rats decreases infarct volume, the number of neutrophils and activated microglia [4] , interferon gamma (IFNγ) levels, and infiltrating immune cells in the brain [19] . In mice, splenectomy prior to tMCAO decreased infarct volume, brain IFNγ levels, and did not increase poststroke infections [5] . Brain water content was significantly lower in splenectomized animals compared to intact animals prior to ICH [6] . Splenectomy immediately after TBI was found to decrease neural injury in two different models of experimental TBI [18, 16, 17] , both of which create areas of ischemia from vessel damage and edema following TBI. As an alternative to splenectomy, irradiation of the spleen 4 h post-tMCAO decreases infarct volume in rats similar to the effects of splenectomy prior to pMCAO. Splenic irradiation causes a temporary decrease in splenocytes which does not result in widespread immunosuppression [20] . Microglia, like Kupffer cells, are tissue-specific macrophages which indicate the spleen is influencing microglia in a similar manner, leading to increased neural injury following ischemic brain injury.
Stem Cell Therapies and the Spleen
Further insight into the role of the spleen has been provided by studies using cellular therapies in experimental models of brain ischemia. Human umbilical cord blood (HUCB) cells [21] [22] [23] , hematopoietic stem cells (HSC) [24] , bone marrow stem cells (BMSC) [25] , and neural stem cells (NSC) [6] have all been shown to reduce neural injury in experimental models of stroke. All stem cells are more efficacious when administered systemically, compared to intracerebral administration. When administered systemically, stem cells migrate to the injured brain and the spleen, and in some cases have been shown to modulate the immune response to stroke [6, 24, 25, 21] , which might be one of the reasons this injection route is more efficacious. Ninety-five percent of BMSC are found in the spleen following systemic administration after MCAO [25] . Even NSCs migrate to the spleen following ICH and are not as efficacious when combined with splenectomy. NSCs were found to be in direct contact with CD11b + splenocytes [6] , which suggests that part of the neuroprotection provided by NSCs involves interacting with the spleen. HUCB cells are another cell type that has been shown to interact with splenocytes. Systemic administration of HUCB cells 24 h post-pMCAO results in altered splenic T cell responses to concanavalin A. Splenic T cells had decreased cell proliferation and decreased production of inflammatory cytokines TNFα and IFNγ, with an increase in the production of the anti-inflammatory cytokine IL-10. HUCB cells also prevent the decrease in spleen size seen at 48 h in rats. This effect is thought be mediated by HUCB cells sequestering immune cells in the spleen following MCAO, preventing their release into systemic circulation [26] . These experiments suggest stem cell therapies work in part by modulating the immune response to stroke, specifically at the level of the spleen.
Splenic Size Decreases Reacting to Stroke
The spleen has been found to decrease in size following pMCAO in rats [26] and tMCAO in mice [27] . The spleen transiently decreases in size from 24 to 72 h following pMCAO in rats [28] . A catecholamine (CA) surge occurs following damage to the insular cortex, an area mainly perfused by the MCA, which may be responsible for this reduction in size. Activation of the α 1 adrenergic receptors on the splenic smooth muscle capsule results in contraction of the splenic capsule, which leads to the decrease in spleen size. Administration of prazosin, an α 1 adrenergic receptor antagonist, prevents the decrease in spleen size following pMCAO [29] . Spleen size has also been inversely correlated with infarct volume in rats following pMCAO, with smaller spleen sizes correlating with larger infarcts [26] . The splenic response in mice following tMCAO appears to be different from the response observed in rats following pMCAO. The spleens of mice continually decrease in size following tMCAO out to 96 h. This decrease in spleen size appears to be due to apoptosis of the spleen and a loss of the germinal B cell centers. The only immune cell population that has been shown to decrease in number following tMCAO in mice is B cells [27] . Another study in mice with tMCAO found the spleen continues to decrease in size out to 7 days post-tMCAO [30] .
There are several reasons that could explain the observed differences in the splenic response to MCAO. The studies were performed in different animal species, mice compared to rats. There are known differences in the mouse immune system compared to other mammals, including rats and humans. One of two of the major differences with mice is that non-antigen-presenting cells do not upregulate major histocompatibility complex (MHC) II in response to IFNγ, whereas rat and human cells do upregulate MHC II in response to IFNγ [31] . Additionally, activated mice T cells do not express MHC II, unlike rat and human activated T cells [32] . While it is not known why the mouse immune system differs in T cell response, these observations show that rat and human T cell responses are similar. Another similarity between rats and humans is the transient decrease in spleen size observed after stroke.
In order to truly understand the role the spleen plays in patients following stroke, studies are being conducted that examine spleen size in stroke patients. One such study currently being conducted has produced preliminary data indicating that the spleen in individuals who have suffered a stroke decreases in volume initially, <6 h to 3 days, and slowly begins to increase in volume starting at day 4 and continuing out to 8 days following the stroke. An individual who suffered a severe stroke and ultimately died had spleen volumes that continued to decrease as their National Institutes of Health Stroke Scale (NIHSS) score also progressively increased, indicating a worsening of neurological symptoms. Two other individuals who had better outcomes had spleens that initially decreased in volume and began to increase in volume as their NIHSS scores decreased. One of the two individuals had their spleen volume measured 90 days following their stroke, and at 90 days the individual's spleen volume was not different from the measurement taken at discharge [33] . A follow-up to this study determined that the spleen returns to size by 5 days [34] which is similar to the findings in the rat model [28] .
Cellular Immune Response
The BBB protects the brain from exposure to anything harmful in the blood, which includes protection from the peripheral immune system under normal healthy conditions. Generally, the only immune cells present in the brain are the endogenous macrophages, microglia. Occasionally, a T cell may enter the brain but due to the decreased expression of MHC molecules in the CNS, the T cell leaves the brain within 24-48 h [35] . This makes the brain an immunoprivileged site, which is beneficial in protecting the brain from systemic inflammation. However, neural antigens can be seen as foreign to the immune system, resulting in immune responses generated against neural antigens that are present in systemic circulation following brain injuries, including stroke.
Both the innate and the adaptive immune systems play an important role in the inflammatory response following ischemic brain injury. The injured cells of the CNS, in combination with glial cells which become activated after a stroke, express chemotactic molecules, which signal to the peripheral immune system that there is an injury to the brain. Various cytokines cause upregulation of vascular adhesion molecules in endothelial cells and on immune cells. This creates a leaky BBB which allows entry of immune cells into the brain [36] .
Cells of monocytic origin, CD11b + cells, become activated as early as 18 h and are significantly increased in number out to 96 h post-tMCAO in mice [37] . It is not possible to differentiate between microglia and peripheral monocytes/ macrophages, as both types of cells express CD11b. Microglia/macrophages become maximally activated in the brain 72 h post-pMCAO in rats [38] . Neutrophil numbers are significantly increased in the infarcted hemisphere, beginning at 48 h and remain elevated out to 96 h post-tMCAO. As expected with an adaptive immune response, T cells are present in the brain starting 72 h and remain at 96 h post-tMCAO [37] .
Since the spleen decreases in size after ischemic insult, this tissue appears to be the origin of peripheral immune cells in the brain following stroke. Splenocytes labeled in vivo with carboxyfluorescein diacetate succinimidyl ester (CFSE) were traced to the infarct following pMCAO. These labeled splenocytes were also found to decrease in number in the spleen and increase in number within the circulation at 48 h post-pMCAO. CFSE-positive cells were found only in the injured hemisphere of pMCAO animals and were not found in the brains of sham pMCAO animals. Additionally, it appears that the CFSE-positive cells in the brain remain in the vasculature [28] . This observation suggests that splenocytes are releasing factors at the BBB to influence the immune response to the infarcted area.
Lymphocytes have also been shown to be involved in increasing neural injury after an ischemic stroke. [39] . Additionally, severe combined immunodeficiency (SCID) mice, which lack lymphocytes, have reduced infarcts compared to WT mice. SCID mice also have reduced cytokine levels, except for IL-1β, in the brain post-tMCAO [40] .
The reaction of the immune system towards neural antigens, which is orchestrated by Th cells, can be harmful or beneficial following ischemic stroke, depending on how the cells are activated and the environment in which the cells are activated. T cells primed to react with a pro-inflammatory response to myelin oligodendrocyte glycoprotein (MOG) prior to tMCAO had increased infarct volumes in mice [41] and resulted in death following sensitization with myelin basic protein (MBP) prior to tMCAO in rats [42] , when compared to animals primed with a nonneural neutral antigen. However, mice with T cells that are tolerized to MBP prior to tMCAO have decreased infarct volume compared to controls [42] .
Molecular Immune Response
Cytokines have been extensively studied following experimental stroke, as well as in stroke patients. Most of the data regarding cytokines and stroke have been contradictory, as some cytokines have dual roles in the immune response and can be either protective or detrimental depending on the circumstances. Some cytokines can be inflammatory early after a stroke, but provide trophic support to cells at delayed time points. Other cytokines can have survival or inflammatory effects depending on the receptor to which they bind. Additionally, some cytokines are elevated very early following stroke. All the above-stated examples demonstrate why no good therapeutic targets for cytokines have been developed (Table 1) .
In mouse models of tMCAO, mRNA levels of IL-1β, IL-10, and TNFα are elevated 6 h post-tMCAO [43, 44] . All of these cytokines are elevated at a time that is outside the therapeutic window to successfully interfere with their signaling. IL-1β mRNA expression increases early in the brain after an ischemic event and remains elevated out to 96 h posttMCAO [43] . Nonimmune cells in the brain express IL-1β. Primary producers of IL-1β in the brain are astrocytes and microglia [36] . This could explain why IL-1β is the only cytokine that does not have decreased expression in SCID mice following tMCAO [40] . IL-10 is considered an antiinflammatory cytokine and is associated with a Th 2 response. IL-10 −/−m ice have increased infarct volumes compared to WT mice following tMCAO [45] , and mice that overexpress IL-10 have decreased infarct volumes compared to controls following pMCAO [46] . This suggests IL-10 may play a beneficial role following brain ischemia.
TNFα is also expressed early in the brain, and is primarily responsible for the activation of the immune system and recruitment of other immune cells. In addition to being expressed early, TNFα is known to have different effects following brain ischemia. Administration of TNFα has been shown to exacerbate infarct volume in both tMCAO and pMCAO in a dose-dependant manner [47] . However, TNFα −/−m ice had increased infarct volumes compared to WT mice following pMCAO [48] . This suggests TNFα plays a protective role following ischemic stroke. Though, when there is a decrease in TNFα production, by inhibiting TNFα converting enzyme (TACE), prior to and following pMCAO TACE-inhibited rats demonstrated decreased infarct volume and reduced neurological deficits compared to control rats [49] . In addition, blocking TNFα with a neutralizing antibody injected intracerebroventricularly (i.c.v.) 15 min post-tMCAO in mice decreased infarct volume; however, administration of the same antibody 3 days post-tMCAO did not decrease infarct volume [45] . TNFα has also been linked to the upregulation of manganese superoxide dismutase (Mn-SOD), an important anti-oxidant enzyme that is believed to play a role in ischemic preconditioning in stroke [50] . All of the contradictory results in experimental stroke with TNFα could be due to the two different TNFα receptors and the subsequent cellular processes induced by these receptors. The two TNFα receptors, when activated, can result in different cellular responses depending on the cell type or the presence of both receptors on the same cell. TNFα can initiate a response resulting in apoptosis and the production of cytokines, or be protective by preventing apoptosis. The two different receptors, TNFαR1 and TNFαR2, result in a combination of different cellular responses. TNFαR1 has an intracellular death domain that can divert the cellular response to [46] -Splenectomy prior to MCAO decreases infarct volume and IFNγ levels in the brain [19] TNFα in a Fas-associated protein with a death domain (FADD) towards apoptosis, or the binding of TNF receptorassociated protein 2 (TRAP2), which leads to the transcription of anti-inflammatory factors. FADD signals to activate caspase 8, leading to apoptosis. TRAP2 leads to the activation of NF κ B and c-JUN which induce anti-apoptotic, antiinflammatory, and cellular protective proteins [50] . TNFαR1 is expressed on all cells, while TNFαR2 is expressed only on oligodendrocytes, astrocytes, T cells, myocytes, endothelial cells, thymocytes, and human mesenchymal stem cells. TNFαR2 does not contain an intracellular cytoplasmic death domain and activation leads to the recruitment of TNF receptor-associated factor 2 (TRAF2). TRAF2 acts similarly to TRAP2 and activates NF κ B, AP1, and mitogen-activated protein kinase (MAPK). The activation of these pathways leads to inflammation, cellular proliferation, and cell survival [51] . In pMCAO experiments with TNFαR knockout mice, TNFαR1 −/−w as associated with neuroprotection, while TNFαR2 −/−w as not associated with neuroprotection [48] .
Studies using cuprizone toxicity as a model of white matter injury found that TNFα is important in the recruitment of oligodendrocyte progenitors to remyelinate axons. This TNFα signaling is mediated through the TNFαR2 [52] . The diverse effects of TNFα can be contributed to many factors, including timing of TNFα signaling and the receptors it signals through; and the contradictory outcomes in animal experiments indicate TNFα is not a good therapeutic target for stroke. Additionally, it is initially elevated outside therapeutically relevant time points to treat stroke. Therefore, despite the fact that there are several FDA approved anti-TNFα therapies, none of them are being used to treat stroke. Another cytokine that has been research extensively in experimental stroke is IL-6. One of the primary reasons a lot of emphasis has been placed on IL-6 is because it is detectable in the serum of stroke patients. Serum IL-6 levels in stroke patients have been shown to be the strongest independent predictive variable of in-hospital mortality following stroke [53] . IL-6 mRNA levels are elevated early in the brain following tMCAO in mice [44] . Despite evidence that IL-6 might be playing a detrimental role in stroke pathology, there has been very little investigation into blocking IL-6 as a therapeutic for stroke. This is likely due to the confounding data from animal studies looking at IL-6 and experimental stroke. IL-6 −/−m ice had infarcts that were not significantly different than their WT or heterozygous littermates following tMCAO [54] . However, IL-6 is known to have pyrogenic activity and IL-6 −/−m ice were found to have lower body temperatures compared to WT mice. Body temperature is known to play an important role following any brain injury, including stroke. When IL-6 −/−m ice had their body temperatures monitored and adjusted to match the WT mice, the IL-6 −/−h ad significantly increased infarct volumes and increased neurologic deficits compared to the WT mice following MCAO [55] . An additional study found i.c.v. administration of recombinant IL-6 prior to pMCAO in rats significantly decreased infarct volume, suggesting IL-6 is directly neuroprotective [56] . A different study using IL-6 −/−m ice found increased infarct volumes compared to WT mice following tMCAO, out to 4 weeks. This study suggested the loss of IL-6 was important for angiogenesis during the recovery phase following stroke [57] .
One reason for the conflicting experimental data could be due to the multiple functions of IL-6. Prior to being named IL-6, this 26-kDa protein was named B cell stimulatory factor 2, IFN-β2, hybridoma/plasmacytoma growth factor, hepatocyte stimulating factor, and 26-kDa protein. Once DNA sequencing was completed, it was discovered that all five proteins were the same molecule [58] . IL-6 signals through one receptor that is a complex of the IL-6R and gp130. The cytoplasmic domain of gp130 contains several signaling motifs that allow IL-6 to signal through ERK or Janus kinases (Jaks) Jak 1 and signal transducers and activators of transcription (STATs) STAT3 or STAT1. STAT3 and STAT1 can form homodimers or a heterodimer once activated. These different signaling pathways allow IL-6 to have diverse effects on a variety of cells and cellular functions. IL-6 is important for liver regeneration, angiogenesis, bone, cartilage, and lipid metabolism, iron homeostasis, and is known to promote cancer cell survival. The immune functions that IL-6 contributes to include promoting neutrophil production and recruitment, enhancing antibody production by B cells, and working with transforming growth factor beta (TGFβ) to increase the production of pro-inflammatory Th 17 cells. Th 17 cells are thought to play a major role in autoimmune diseases [59] . IL-6 plays many different roles following stroke depending on the exact timing after the stroke, which makes targeting IL-6 as a treatment after stroke problematic.
Out of numerous studies on cytokines in animals and stroke patients, there has yet to be a therapeutic developed for stroke. Many cytokines are part of the innate immune response and increase rapidly following stroke, while other cytokines have dual roles following stroke or serve a potentially protective function. IFNγ is one cytokine that has not been extensively studied and could be promising in the development of a delayed therapeutic option, which could strictly address the pro-inflammatory response. IFNγ is the signature cytokine of the adaptive immune Th 1 response.
Interferon Gamma Signaling Following Stroke
IFNγ is a pleiotropic cytokine that can affect cellular processes, ranging from immune cell function to playing a role in vascular leukocyte adhesion. The 34-kDa homodimer is the biologically active form of IFNγ [60] . The half-life of IFNγ in the blood is 1.1 min if it is not bound to heparin or heparin sulfate, and the half-life is increased to 99 min when bound. When IFNγ is injected into the bloodstream, 90 % of the protein is proteolytically cleaved at the carboxyl-terminal within 5-10 min, rendering it inactive. The other 10 % becomes bound to a heparin molecule, increasing its half-life [61] . The biologically active form of IFNγ binds to the IFNγ receptor complex that is comprised of two pairs of transmembrane proteins which signal through the Jak 1 or Jak 2 and STAT1. Of the two different proteins that make up the IFNγ receptor, the IFNγR 1, or the α-chain, is the part of the receptor that binds IFNγ. Following binding of IFNγ, the α-chain dimerizes with another α-chain. Then, the second protein IFNγR 2 , or the β-chain, dimerizes with another β-chain to the complex. The β-chain is primarily involved in signaling, whereas the α-chain is primarily involved in binding IFNγ. Jak 1 is associated with the α-chain and Jak 2 is associated with the β-chain. Once IFNγ binds, the Jaks become phosphorylated and phosphorylate STAT1α, which homodimerizes and translocates to the nucleus to affect transcription. The IFNγ receptor is expressed on every cell in the body but its density varies from cell type to cell type, with immune cells, monocytes in particular, having the highest expression.
The primary producers of IFNγ are T cells, CD4 + Th 1 cells, CD8 + T cells, and NK cells. IFNγ production is induced by IL-12, IFNα, and even by IFNγ through positive feedback. IFNγ induces the production of more IL-12 by macrophages, which further increase IFNγ production. In addition to increasing its own expression, IFNγ causes increased expression of proteins involved in the generation of reactive oxygen species (ROS), chemotaxis of more immune cells to the site of injury, upregulation of MHC molecules, and induces isotype switching in B cells [60] . Indirectly, there is also an increase in cellular adhesion molecules on endothelial cells by IFNγ through upregulating chemokines, including monocyte chemoattractant proteins (MCPs), monokine induced by gamma interferon (MIG), interferon-inducible protein 10 (IP-10), IL-8, and interferon-inducible T cell α chemoattractant (I-TAC). With the recruitment of additional immune cells to the site of injury, IFNγ also primes T cells and cells of monocytic origin towards a pro-inflammatory phenotype. IFNγ and its effector molecules prime naïve Th cells to develop into Th 1 cells, blunting the response of other Th subsets. Microglia/macrophages become activated towards a pro-inflammatory state via the upregulation of ROS production and MHC II expression. The primary role that IFNγ plays in the immune response is to increase resistance to bacteria and viruses, particularly intracellular pathogens. To obtain this immune response, the primary target cells of IFNγ in the immune system are macrophages. These cells are also the primary producers of all the chemokines like IP-10, MIG, and I-TAC [62] .
The Detrimental Role of IFNγ Following Ischemic Brain Injury
There are several data in animals and stroke patients indicating IFNγ plays a detrimental role in stroke pathogenesis. IFNγ mRNA is upregulated 2 days post-pMCAO in the brain of rats [63] . Protein levels of IFNγ are elevated in the brain of rats following pMCAO [19] and mice following tMCAO at 72 h post-MCAO [5] . IFNγ protein levels also spike in the spleen 24 h post-pMCAO, and splenectomy decreases IFNγ expression in the brain at 72 h [19, 5] . Administration of simvastatin following tMCAO in mice reduced infarct volume and IFNγ levels in the brain [5] . Additionally, IFNγ [39] . Delayed administration of antibodies directed against IFNγ decreased infarct volume when injected i.c.v. 3 days post-tMCAO, but not earlier [45] . In addition, indirect blocking of IFNγ is neuroprotective. Administration of an anti CD49d (VLA-4) antibody 24 h prior to the MCAO reduced infarct volume and blocked T cells and NK cells from entering the brain following tMCAO. This prevented IFNγ producing cells from entering the injured brain, which decreased IFNγ levels and infarct volume [64] .
In stroke patients who developed an infection, particularly pneumonia, within 15 days of having a stroke had a worse outcome compared to individuals who did not develop an infection regardless of stroke severity. Individuals who developed an infection were more likely to have a Th 1 response to MBP and glial acid fibrillary protein (GFAP) at 90 days poststroke, and individuals who generated a higher Th 1 response to MBP at 90 days were more likely to have a poorer outcome regardless of age or baseline stroke severity [65] . IFNγ is considered a signature cytokine of a Th 1 response, which could implicate IFNγ as being detrimental following stroke in patients when an inflammatory T cell response is generated against brain antigens.
The Generation of an IFNγ-Driven Response to Brain Antigens Following Stroke
IFNγ levels in the spleen and in the brain could become increased due to the elevated levels of circulating catecholamines. Increased levels of circulating norepinephrine (NE) and epinephrine have been found in humans and rats after experiencing a blockage of the MCA [66, 67] . The additional amount of circulating CAs has been attributed to insular cortex damage, which is mainly perfused by the MCA. Damage to this region in patients has also been shown to cause sympathetic dysregulation [66] . Furthermore, NE reduces the ability of Th 1 cells to respond when activated, and this effect is thought to be mediated by the presence of β 2 adrenergic receptors on Th 1 cells [68] . CAs are also thought to induce apoptosis in Th 1 cells leaving stroke patients vulnerable to infections [69] . However, naïve T cells also express β 2 adrenergic receptors. When naïve T cells are exposed to NE, these cells are driven to differentiate into the Th 1 phenotype. Upon reactivation, these cells express 2-4 fold more IFNγ than naïve T cells not exposed to NE [70] . The effect of NE on naive T cells and Th 1 cells may account for the immune dysfunction to pathogens and the increased levels of IFNγ production observed in the spleen following MCAO.
In addition, the cells that become activated in the presence of catecholamines are also exposed to brain-derived antigens that enter circulation following stroke [71, 72] . This could lead to a Th 1 response to brain antigens, which has been shown in animal studies to result in a more severe injury [73] . This response may also be mediated through IFNγ, as IFNγ is considered an indicator of a Th 1 response.
Conclusion
Interferon gamma and the spleen both potentially play important roles in exacerbating neural injury following ischemic stroke. Removal of the spleen has proven that an inflammatory response originating from this organ to stroke is responsible for delayed neurodegeneration. IFNγ levels are increased as part of this splenic inflammatory response and results in delayed activation of microglia/macrophages in the brain that is detrimental to the survival of compromised neural cells. IFNγ is also known to induce several proteins, many of which are chemokines. IP-10 is of particular interest as it plays a role in influencing the differentiation of naïve Th cells to become Th 1 cells, and is a strong chemoattractant for Th 1 cells while subsequently blocking the activation of Th 2 cells. The recruitment of more pro-inflammatory Th 1 cells would result in more IFNγ production and further activation of microglia/ macrophages. This would create a feed-forward inflammatory environment in the stroke-injured brain (Fig. 1a) . Blocking or interfering with IFNγ signaling could provide a targeted approach to blunting just the pro-inflammatory response and not the whole immune response that is seen with broad immunosuppressants, like cyclosporine (Fig. 1b) .
Experimental therapeutics that target the spleen or IFNγ have shown translational promise as stroke treatments. Splenectomy prior to stroke is not a practical translational therapy for stroke. Studies using cellular therapies to treat experimental stroke have shown that this approach is more efficacious when administered systemically relative to directly into the brain. Besides the injured brain, these cells migrate to the spleen and their presence inhibits its inflammatory response. A recent study demonstrated targeted irradiation of the spleen at 4 h post-tMCAO decreased infarct volume, did not damage surrounding organs, and did not cause severe immune suppression that resulted in poststroke infections [20] . Another study examined administration of an FDA-approved statin, simvastatin, following tMCAO. Administration of a statin at the time of reperfusion decreased infarct volume at 5 days, prevented increased IFNγ levels in the brain at 3 days, and Fig. 1 The generation of an interferon gamma driven immune response following stroke. After a stroke, there is an increase in systemic circulating catecholamines that causes a decrease in spleen size. At the same time, there is an increase in splenic interferon gamma (IFNγ). There is then a delayed increase in the expression of IFNγ in the brain, which activates microglia and macrophages. Activation of these cells causes increased expression of interferon-inducible protein 10 (IP-10) and increased neural injury. The elevated levels of IP-10 create a pro-inflammatory loop by recruiting more IFNγ-producing cells to the brain (a). Blocking or interfering with IFNγ signaling is a potential therapeutic option as blocking IFNγ would decrease microglia/macrophage activation, IP-10 expression, and prevent further increases in IFNγ in the brain resulting in decreased neural injury following stroke (b) prevented splenic atrophy, which is seen in mice after stroke. Additionally, there was a decrease in poststroke lung infections despite decreased levels of IFNγ in the brain [5] . These two preclinical studies demonstrate the effectiveness of two different therapeutic strategies that target the spleen and/or IFNγ leading to neuroprotection without suppressing normal immune function. Further investigation into these treatments and treatments similar to the previously mentioned studies is warranted.
